Introduction
Cardiovascular diseases are the principal causes of death and disability in diabetics. The increased proinflammatory status and oxidative stress seem to play a major role in the initiation and progression of cardiovascular dysfunction in diabetes mellitus (DM). Hyperglycaemia has been shown to lead to a series of cellular events that increase the production of reactive oxygen species 1 and induce proinflammatory effects 2 that promote the migration of monocytes and vascular smooth muscle cells into the intima and formation of the initial atherosclerotic lesions. 3 On the other hand, neurohumoral factors, such as the renin angiotensin and sympathetic nervous system, are activated in patients with DM and cardiovascular autonomic neuropathy is frequently observed. In addition, angiotensin II and sympathetic nervous system overactivity are factors that regulate cytokine production and oxidative stress, at least in part, 4, 5 thus contributing to the development of atheromatosis and cardiovascular complications.
The renin angiotensin aldosterone system (RAAS) has been recognized as an important therapeutic target for the prevention of cardiovascular complications in patients with type 2 DM. Its inhibition with angiotensin-converting enzyme inhibitors (ACE-i) has been shown to improve prognosis and to have multiple beneficial effects in diabetic patients with hypertension. 6 However, it has been demonstrated that perindopril-a frequently used ACE-i that is known to have favourable effects on sympathetic nervous system overactivity in diabetic hypertensives 7 -improves arterial elasticity 8 in nonhypertensive diabetic patients, suggesting that its action in diabetes is independent of its effect on blood pressure (BP).
The aim of this study was to investigate the effect of perindopril on indexes of systemic inflammation and oxidative stress in the peripheral circulation of non-hypertensive patients with type 2 DM. We also used 123 I-metaiodobenzylguanidine ( 123 I-MIBG) myocardial scintigraphy to examine the effect of the drug on the disturbances of left ventricular myocardial adrenergic innervation that may be seen in these patients.
Materials and methods

Study population
The study population was recruited from the cardiology outpatients' department. All participants had type 2 DM (World Health Organisation 9 criteria), diagnosed at an age over 30 years and controlled by diet or blood glucose-lowering agents for at least 6 months. All were normotensive (BP o130/85 mm Hg) with no indications of other organic heart disease. The following were criteria for exclusion: heavy smokers, pregnant or lactating women, type 1 DM or secondary diabetes, previous or ongoing treatment with ACE-i, angiotensin receptor blockers, antioxidant or immunosuppressive agents, systolic BP o100 mm Hg or diastolic BP o50 mm Hg, poor glycaemic control, hyperuricaemia, previous history or medication for hypertension, cerebrovascular, liver or renal disease, serum potassium 45 mEq l À1 , albumin excretion rate 4200 mg min À1 , history of drug or alcohol abuse, any chronic inflammatory or other infectious disease during the last 6 months, uncontrolled hypothyroidism. The patients were randomly allocated by a computer algorithm to one of two groups for treatment with 4 mg perindopril or placebo in an open-label, parallel-group, randomized design.
Before randomization, patients underwent an evaluation that included medical history, 12-lead electrocardiography, clinical and laboratory assessment during a run-in period lasting 3 weeks. BP was measured in duplicate on four separate visits, between 0800 and 1000 hours, with the patient in a seated position. On the last day of the run-in period, 24-h ambulatory BP monitoring was performed. Patients were required to visit the outpatients' clinic 1, 3 and 6 months after the initiation of treatment. At the start of the study and at each follow-up all patients had their medical history recorded and underwent clinical examination, haematological and biochemical profile, 24-h albuminuria and 24-h ambulatory BP monitoring. Before and 6 months after the initiation of therapy all patients underwent an echocardiographic examination, with thallium TI 201 stress myocardial scintigraphy and 123 I-MIBG myocardial scintigraphy for assessment of myocardial perfusion and adrenergic innervation. No patient was taking any medication known to interfere with 123 I-MIBG uptake. Concomitant medications remained unchanged. Patients gave written informed consent. The ethics committee of this hospital approved the study.
Biochemical analyses
Blood samples were obtained 24 h before and 6 months after the initiation of treatment. Patients were asked to refrain from eating and drinking alcohol or coffee for 12 h before each blood sampling. All studies were performed between 0900 and 1100 hours and all participants were rested for 430 min in a supine position. All blood samples were drawn from an antecubital vein. Serum or plasma was collected in tubes containing ethylenediaminetetraacetic acid (EDTA) and stored at below À80 1C until assay. Plasma interleukin-6 (IL-6), and tumour necrosis factor-a (TNF-a) levels were determined by high-sensitivity solid-phase enzymelinked immunosorbent assays, according to the manufacturer's instructions (R&D Systems Inc., Minneapolis, MN, USA) with mean minimum detectable levels of 0.039 and 0.12 pg ml À1 , respectively. A colorimetric method (OxyStat, Biomedica, Austria) was used to determine the concentration of total peroxides (TP) in EDTA-plasma samples. Briefly, the peroxide concentration is determined by reaction of the biological peroxides with peroxidase, with a subsequent colour reaction using tetramethylbenzidine as a substrate, read at 450 nm. A calibrator is used to calculate the concentration of biological peroxides in the sample (one-point calibration), with a detection limit of 7 mmol l À1 . Samples, controls, and standards were run in duplicate with all intra-and inter-assay coefficients of variance less than 10%.
I-MIBG scintigraphy
On the day of the 123 I-MIBG scintigraphy all patients and controls were instructed to fast for 6 h. Lugol's solution (1 ml) was given orally 2 h before the slow intravenous injection of 5 mCi 123 I-MIBG (Mallinckrodt Inc., St Louis, MO, USA; specific activity 74 MBq mg À1 ). At 10 min and 4 h after tracer injection a 10-min static acquisition was carried out in the anterior view of the chest, using a General Electric (GE Medical Systems, Milwaukee, WI, USA), large field of view, single-head gamma camera fitted with a low-energy, all purpose, parallel hole collimator. A 20% energy window centred on 157 keV and a 128 Â 128 matrix size were used. After the delay planar image, single-photon emission-computed tomography (SPECT) was carried out with a dual-head gamma camera (GE Medical Systems). Thirty-two projections (50 s) were obtained over a 1801 arc, from left posterior oblique to right anterior oblique, and images were stored using a 64 Â 64 matrix. Transaxial, sagittal and oblique tomograms were obtained using a nuclear medicine computer (software: GENIE v.2.5H, 99224, rev. 137). Cardiac uptake was quantified in all planar views. A 7 Â 7 pixel region of interest was drawn over the cardiac region and another 7 Â 7 region of interest over the upper mediastinum area. The heart to mediastinum (H/M) activity ratio was then computed to quantify cardiac 123 I-MIBG accumulation. Visual analysis of seven segments was carried out on the SPECT image. The segments were numbered as follows: (1) anterior, (2) anterolateral, (3) inferolateral, (4) inferior, (5) interoseptal, (6) anteroseptal and (7) apex. The SPECT images were reviewed by two experienced nuclear medicine physicians who were blind to the patients' clinical history. The grading of each segment was made on a four-point scale from 0 to 3, where 0 ¼ normal radioisotopic uptake (475% of peak activity), 1 ¼ mildly reduced radioisotopic uptake (50-70% of peak activity), 2 ¼ moderately reduced radioisotopic uptake (25-50% of peak activity), 3 ¼ absence of detectable tracer in a segment or severe reduction of the uptake (o25% of peak activity). The total defect score was calculated as the sum of the 7 regional scores.
Statistical analyses
Summary descriptive statistics are given as mean ± s.d. for continuous variables, and as percentages for categorical variables. Independent samples t-test or Mann-Whitney test, as appropriate, were employed to compare continuous parameters between the two patient groups. Paired samples t-test or Wilcoxon test, as appropriate, were used to assess treatment changes within each group. 95% confidence intervals of mean treatment changes were also constructed to provide a better picture of their magnitude. Fisher's exact test or w 2 -test was used to compare categorical variables between the two groups. All comparisons were performed at the two-sided 5% level of significance.
Results
A total of 69 patients were randomly assigned to receive perindopril or placebo. Seven patients dropped out during the study (four perindopril, three placebo), two in the perindopril group because of coughing and the remainder because of noncompliance. Of the remaining 62 patients, 32 were in the perindopril group and 30 in the placebo group. The clinical, demographic data and all baseline measurements did not differ significantly between the two groups ( Table 1) . A total of 20 patients with angina-like symptoms had undergone coronary angiography to rule out coronary artery disease.
There were no significant changes in clinical characteristics during the study in either group. There was a trend to a reduction in albuminuria in the perindopril group at 6 months ( Table 2) .
Comparison of cytokines and TP levels before and after treatment Perindopril treatment was associated with a significant reduction in levels of cytokines and TP at the end of 6 months compared to the baseline values. IL-6 showed a significant decrease in the perindopril group (Po0.001), whereas no significant change was observed in the placebo group (P ¼ 0.17). Similarly, TNF-a and TP levels were decreased at the end of follow-up in the perindopril group but not in controls (Po0.001 and P ¼ 0.001 for perindopril versus P ¼ 0.15 and P ¼ 0.062 for placebo, respectively) ( Table 2 ). More precisely, IL-6, TNF-a and TP in the perindopril group decreased by an average of 0.6 pg ml À1 (95% CI: 0.39-0.79), Abbreviations: BP, blood pressure; H/M, heart to mediastinum activity ratio; IL-6, interleukin-6; TNF-a, tumour necrosis factor-a. The effect of perindopril on myocardial adrenergic innervation of the left ventricle An overwhelming majority of the patients in the study (31 in the perindopril group and 28 controls) showed adrenergic innervation defects in the left ventricular myocardium. Most of the patients had defects in the inferolateral wall (25 in the perindopril group and 24 controls), apical wall (20 perindopril, 14 controls), inferior wall (18 perindopril, 12 controls) and anterolateral wall (12 perindopril, 11 controls). Some had defects in the anterior wall (7 perindopril, 10 controls) and some in the interoseptal wall (11 perindopril, 8 controls) . In contrast to the placebo group, we found a significant improvement in the regional myocardial adrenergic innervation defects in most of the myocardial walls under perindopril treatment. More specifically, perindopril patients had a very significant reduction in total defect score (from 6.03±5.7 to 3.56 ± 5.6, Po0.001) while in the controls only a small, non-significant increase was observed (from 6.06±6.4 to 6.96±6.2, P ¼ 0.172). Similarly, the quantitative analysis showed no significant change from baseline in the H/M ratio at 10 min or at 4 h in the placebo group, while this ratio was significantly increased in the perindopril group (Table 2) .
Discussion
Our findings demonstrate for the first time that the addition of an ACE-i may improve systemic inflammatory status, oxidative stress and cardiac sympathetic nerve activity in normotensive patients with type 2 DM.
Type 2 DM has been proposed as an inflammatory condition, in which there is an increase in the synthesis of cytokines such as TNF-a and IL-6.
10 IL-6 is a pleiotropic cytokine that has been proposed as a predictor of cardiovascular mortality and future myocardial infarction 11 and regulates the expression of other inflammatory cytokines, including TNF-a. Cytokine production promotes cell activation and migration, resulting in the formation of atherosclerotic lesions. 3 In addition, diabetic subjects have decreased antioxidant activity and an increased oxidative burden.
Recent evidence suggests that ACE-i can be advantageous for the prevention and halting the progression of both micro-and macrovascular complications in patients with DM. 6 However, the latest findings indicate that the action of ACE-i in diabetes is independent of its effect on BP and could benefit even those patients who have not exhibited hypertension. More precisely, it has been reported that ACE inhibition with perindopril improves maximal achieved myocardial perfusion 16 as well as arterial elasticity 8 in non-hypertensive patients with diabetes.
It has been suggested that the beneficial effect of ACE-i in cardiovascular diseases may involve action Abbreviations: BP, blood pressure; H/M, heart to mediastinum activity ratio; IL-6, interleukin-6; TNF-a, tumour necrosis factor-a.
on the sympathetic nervous system and inflammatory status. It is well known that angiotensin II augments vascular inflammation and endothelial dysfunction induces the production of reactive oxygen species and inflammatory cytokines, 17 while RAAS blockade leads to a reduction in oxidative stress 18 and inflammation. 19 However, there is a paucity of definite data regarding the anti-inflammatory effects of ACE-i in patients with type 2 DM and no other cardiovascular disorder. We found that perindopril caused a significant drop in levels of IL-6, TNF-a and oxidative stress in such patients. Since angiotensin II has been shown to be a proinflammatory mediator, the anti-inflammatory action of perindopril is easy to explain.
Another important finding was that perindopril treatment significantly improved the disturbances of left ventricular myocardial adrenergic innervation that the overwhelming majority of our patients exhibited. This is in agreement with the findings of earlier studies that ACE inhibition improves measures of diabetic autonomic neuropathy. 20 However, there is a lack of data regarding the effect of ACE-i on myocardial adrenergic innervation in patients with type 2 DM. The majority of our patients showed decreased values of H/M and myocardial adrenergic innervation defects, which are thought to be due to functional and structural disturbances caused by an increase in sympathetic activity. 21 More specifically, these phenomena might be the result of either a decreased number of cardiac sympathetic nerve endings, a decreased function type 1 uptake, or accelerated release from storage vesicles. Our 123 I-MIBG findings with ACE-i are consistent with those in cardiovascular diseases that involve cardiac sympathetic overactivity, such as heart failure and essential hypertension. Angiotensin II is known to facilitate norepinephrine release at presynaptic sites 22 and acts as a sympathetic nervous system activator. 23 In addition, ACE inhibition may lead to enhanced prostaglandin synthesis, which may inhibit norepinephrine release at presynaptic sites. 24 Thus, blocking the RAAS, which is activated in patients with DM, may improve the disturbed sympathetic nervous system activity. In addition, early structural changes in the myocardium, asymmetrical changes of left ventricular wall mass without clinically relevant functional consequences, 25 have been reported in diabetic patients and could cause local disturbances of adrenergic innervation. The favourable effect of ACE-i on left ventricular remodelling could improve those regional disturbances. However, the possibility remains that all these beneficial results of perindopril are partly due to the drug's systemic haemodynamic effects, even though we found no significant changes in BP. Nevertheless, it must be emphasized that the amelioration of the scintigraphic disturbances may not be translated into real biological benefit unless more data about the clinical outcome are available in those patients.
The fact that BP did not decrease significantly, though somewhat surprising, can be explained by the fact that in normotensive subjects other mechanisms apart from the RAAS, such as autonomic reflexes and vasoactive substances, can successfully maintain BP homeostasis. Our findings agree with those of previous studies that used perindopril in similar doses and found minimal haemodynamic effects in normotensives. 8, 26 It should be emphasized that the relatively small number of patients included in this study was a limitation that prevents the drawing of certain conclusions concerning the above results. Because the selection of participants was based strictly on normal BP and normal myocardial perfusion SPECT scintigraphy, it was difficult to recruit a larger number of subjects.
In addition, not all our patients underwent coronary angiography to rule out subclinical coronary artery disease, which might affect cardiac adrenergic innervation and inflammatory markers. However, we considered it unethical to subject our patients to this examination without any clear indication. We also do not know whether the dietary habits, and particularly sodium intake, differed between groups. There is a chance, albeit small, that this might have affected our results.
In conclusion, our data indicate that the addition of ACE-i to the medication of non-hypertensive diabetic type 2 patients may improve the disturbed myocardial sympathetic innervation that these patients can exhibit, while also improving their systemic inflammatory status and oxidative stress. This is of particular interest, because inflammation, oxidative stress and sympathetic nervous system dysfunction have been recognized as pro-atherogenic factors. These abnormalities promote endothelial dysfunction that may occur at a very early stage of diabetic cardiomyopathy and atheromatic disease and may not be detectable by routine clinical examinations. Our findings demonstrate that, even in normotensive patients with type 2 DM, additional cardiovascular benefit might be obtained by the What is known about the topic K ACE-i have favourable effects on sympathetic nervous system overactivity in diabetic hypertensives K ACE-i improves arterial elasticity in non-hypertensive diabetic patients, suggesting that their action in diabetes is independent of its effect on blood pressure 
